Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Alkermes Depression Drug Hits Important Goal in Late-Stage Study

By Ryan Bushey | October 24, 2016

Alkermes saw its shares surge on Thursday after the Dublin, Ireland-based company announced new trial data regarding its experimental drug to treat major depressive disorder, ALKS 5461.

Initial results from a randomized Phase 3 study featuring 407 patients had shown ALKS 5461 was able to significantly improve depression symptoms in patients who had an inadequate response to other standard therapies, wrote The Wall Street Journal.

ALKS 5461 is a once-daily pill treatment designed to act as a neuromodulator. It’s comprised of samidorphan and buprenorphine, which is a combination of drugs that helps rebalance brain function that becomes dysregulated in the state of depression.

The lower dose of the drug did not achieve statistical significance when compared to placebo whereas the two tested higher doses of ALKS 5461 outperformed placebo on two different depression scales, according to Reuters. Some adverse events were reported like nausea and fatigue although this was consistent with occurrences in previous studies.

These results signify a turnaround after the company had to cancel two Phase 3 trials earlier this year after the drug failed to meet its primary endpoints.

Alkermes stock rose 43 percent in after-hours trading on Thursday adding more than $3 billion to the company’s market value, explained WSJ.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE